4-Hydroxyphenytoin (BioDeep_00000023174)

   

human metabolite Endogenous blood metabolite


代谢物信息卡片


2,4-Imidazolidinedione,5-(4-hydroxyphenyl)-5-phenyl-

化学式: C15H12N2O3 (268.0847882)
中文名称: 5-(4-羟基苯基)-5-苯基乙内酰脲
谱图信息: 最多检出来源 Homo sapiens(blood) 2.31%

分子结构信息

SMILES: C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=C(C=C3)O
InChI: InChI=1S/C15H12N2O3/c18-12-8-6-11(7-9-12)15(10-4-2-1-3-5-10)13(19)16-14(20)17-15/h1-9,18H,(H2,16,17,19,20)

描述信息

4-Hydroxyphenytoin, also known as hydroxyphenytoin or 4-HPPH, belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. 4-Hydroxyphenytoin is a metabolite of the anti-seizure medication phenytoin (PHT) and is excreted in the urine (PMID: 15855726).

同义名列表

22 个代谢物同义名

2,4-Imidazolidinedione,5-(4-hydroxyphenyl)-5-phenyl-; 5-(4-Hydroxyphenyl)-5-phenylimidazolidine-2,4-dione; 5-(4-Hydroxyphenyl)-5-phenyl-2,4-imidazolidinedione; 4-(4-hydroxyphenyl)-4-phenyl-4H-imidazole-2,5-diol; 5-(4-hydroxyphenyl)-5-phenylimidazole-2,4-diol; 5-(p-Hydroxyphenyl)-5-phenyl-hydantoin; 5-(4-Hydroxyphenyl)-5-phenylhydantoin; 5-(p-Hydroxyphenyl)-5-phenylhydantoin; (p-Hydroxyphenyl)phenylhydantoin; (Hydroxyphenyl)phenylhydantoin; Hydroxyphenytoin, 11C-labeled; Hydroxyphenytoin, (+-)-isomer; Hydroxyphenytoin, (R)-isomer; Hydroxyphenytoin, (S)-isomer; p-Hydroxydiphenylhydantoin; 4-Hydroxydiphenylhydantoin; Hydroxydiphenylhydantoin; Para-hydroxyphenytoin; 4-Hydroxyphenytoin; p-Hydroxyphenytoin; Hydroxyphenytoin; 4-HPPH



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(5)

BioCyc(0)

PlantCyc(0)

代谢反应

52 个相关的代谢反应过程信息。

Reactome(50)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(1)

PharmGKB(1)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Zhen Wang, Xiaoyu Wang, Zhe Wang, Xin Lv, Hang Yin, Wei Li, Wenli Li, Lili Jiang, Yong Liu. Potential herb-drug interaction risk of thymoquinone and phenytoin. Chemico-biological interactions. 2022 Feb; 353(?):109801. doi: 10.1016/j.cbi.2022.109801. [PMID: 34998822]
  • Wei Li, Zhen Wang, Xiaoyu Wang, Xiaowei Cao, Caili Bi, Lili Jiang, Shuna Cui, Yong Liu. Risk prediction of drug-drug interaction potential of phenytoin and miconazole topical formulations. Chemico-biological interactions. 2021 Jul; 343(?):109498. doi: 10.1016/j.cbi.2021.109498. [PMID: 33961833]
  • Sheng Feng, Brandi Bridgewater, Erin C Strickland, Gregory McIntire. A Rapid LC-MS-MS Method for the Quantitation of Antiepileptic Drugs in Urine. Journal of analytical toxicology. 2020 Oct; 44(7):688-696. doi: 10.1093/jat/bkaa095. [PMID: 32744607]
  • Xiang-Yang Li, Yong-Nian Liu, Ming Yuan, Yong-Ping Li, Ying-Zhong Yang, Jun-Bo Zhu. [Effect of high altitude hypoxia on the activity and protein expression of CYP2C9 and CYP2C19]. Yao xue xue bao = Acta pharmaceutica Sinica. 2012 Feb; 47(2):188-93. doi: NULL. [PMID: 22512029]
  • Zenghan Tong, David S Hage. Characterization of interaction kinetics between chiral solutes and human serum albumin by using high-performance affinity chromatography and peak profiling. Journal of chromatography. A. 2011 Sep; 1218(39):6892-7. doi: 10.1016/j.chroma.2011.08.026. [PMID: 21872871]
  • Theresa Aliwarga, James C Cloyd, Varun Goel, Richard C Brundage, Susan E Marino, Ilo E Leppik, Rory P Remmel. Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. Therapeutic drug monitoring. 2011 Feb; 33(1):56-63. doi: 10.1097/ftd.0b013e3182081089. [PMID: 21233690]
  • Jin Zhou, Timothy S Tracy, Rory P Remmel. Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug metabolism and disposition: the biological fate of chemicals. 2011 Feb; 39(2):322-9. doi: 10.1124/dmd.110.035030. [PMID: 21030469]
  • F Jabbaribar, S A Mortazavi, A Jouyban. Determination of phenytoin and its major metabolite in human serum by MEKC. Journal of chromatographic science. 2009 Nov; 47(10):877-80. doi: 10.1093/chromsci/47.10.877. [PMID: 19930798]
  • Carmin Marc Kalorin, Ross Bauer, Mark D White. Phenytoin metabolite renal calculus: an index case. Journal of endourology. 2008 Aug; 22(8):1665-8. doi: 10.1089/end.2007.0410. [PMID: 18620500]
  • Alaa Khedr, Mohamed Moustafa, Ashraf B Abdel-Naim, Abdulrahman Alahdal, Hisham Mosli. High-performance liquid chromatographic method for determination of phenytoin in rabbits receiving sildenafil. Analytical chemistry insights. 2008 Apr; 3(?):61-7. doi: 10.4137/aci.s658. [PMID: 19609390]
  • Tobias Klaassen, Alexander Jetter, Dorota Tomalik-Scharte, Dirk Kasel, Julia Kirchheiner, Ulrich Jaehde, Uwe Fuhr. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. European journal of clinical pharmacology. 2008 Apr; 64(4):387-98. doi: 10.1007/s00228-007-0416-z. [PMID: 18071681]
  • Upendra A Argikar, James C Cloyd, Angela K Birnbaum, Ilo E Leppik, Jeannine Conway, Smita Kshirsagar, William S Oetting, Erin C Klein, Rory P Remmel. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy research. 2006 Sep; 71(1):54-63. doi: 10.1016/j.eplepsyres.2006.05.015. [PMID: 16815679]
  • Corey M Ohnmacht, Shirley Chen, Zenghan Tong, David S Hage. Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 May; 836(1-2):83-91. doi: 10.1016/j.jchromb.2006.03.043. [PMID: 16621742]
  • Aurel C Allabi, Jean-Luc Gala, Yves Horsmans. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenetics and genomics. 2005 Nov; 15(11):779-86. doi: 10.1097/01.fpc.0000174787.92861.91. [PMID: 16220110]
  • Pradip Datta, Deven Scurlock, Amitava Dasgupta. Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue. Therapeutic drug monitoring. 2005 Jun; 27(3):305-8. doi: 10.1097/01.ftd.0000164315.13825.dd. [PMID: 15905800]
  • Hiroyuki Yamanaka, Miki Nakajima, Yusuke Hara, Miki Katoh, Osamu Tachibana, Junkoh Yamashita, Tsuyoshi Yokoi. Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. Drug metabolism and pharmacokinetics. 2005 Apr; 20(2):135-43. doi: 10.2133/dmpk.20.135. [PMID: 15855726]
  • William L Roberts, Petrie M Rainey. Phenytoin overview--metabolite interference in some immunoassays could be clinically important. Archives of pathology & laboratory medicine. 2004 Jul; 128(7):734; author reply 734-5. doi: 10.5858/2004-128-735-ir. [PMID: 15229987]
  • Miki Nakajima, Nozomi Sakata, Noriko Ohashi, Toshiyuki Kume, Tsuyoshi Yokoi. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2002 Nov; 30(11):1250-6. doi: 10.1124/dmd.30.11.1250. [PMID: 12386132]
  • Cuyue Tang, Yuh Lin, A David Rodrigues, Jiunn H Lin. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug metabolism and disposition: the biological fate of chemicals. 2002 Jun; 30(6):648-54. doi: 10.1124/dmd.30.6.648. [PMID: 12019190]
  • Y G Kim, M K Cho, J W Kwon, S G Kim, S J Chung, C K Shim, M G Lee. Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. International journal of pharmaceutics. 2001 Oct; 229(1-2):45-55. doi: 10.1016/s0378-5173(01)00815-8. [PMID: 11604257]
  • Y Caraco, M Muszkat, A J Wood. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics. 2001 Oct; 11(7):587-96. doi: 10.1097/00008571-200110000-00005. [PMID: 11668218]
  • Y Iida, S Nishi, A Asada. Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics. Therapeutic drug monitoring. 2001 Jun; 23(3):192-7. doi: 10.1097/00007691-200106000-00002. [PMID: 11360024]
  • F Kamali, W S McLaughlin, D E Ball, R A Seymour. The effect of multiple anticonvulsant therapy on the expression of phenytoin-induced gingival overgrowth. Journal of clinical periodontology. 1999 Dec; 26(12):802-5. doi: 10.1111/j.1600-051x.1999.tb02523.x. [PMID: 10599907]
  • Y Horsmans, V Van den Berge, A Bouckaert, J P Desager. Phenytoin hydroxylation in a healthy Caucasian population: bimodal distribution of hydroxyphenytoin urinary excretion. Pharmacology & toxicology. 1997 Dec; 81(6):276-9. doi: NULL. [PMID: 9444669]
  • I Ieiri, K Mamiya, A Urae, Y Wada, M Kimura, S Irie, T Amamoto, T Kubota, S Yoshioka, K Nakamura, S Nakano, N Tashiro, S Higuchi. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. British journal of clinical pharmacology. 1997 Apr; 43(4):441-5. doi: 10.1046/j.1365-2125.1997.00572.x. [PMID: 9146858]
  • W Tassaneeyakul, D J Birkett, M C Pass, J O Miners. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. British journal of clinical pharmacology. 1996 Dec; 42(6):774-8. doi: 10.1046/j.1365-2125.1996.00496.x. [PMID: 8971435]
  • D E Ball, W S McLaughlin, R A Seymour, F Kamali. Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients. Journal of periodontology. 1996 Jun; 67(6):597-602. doi: 10.1902/jop.1996.67.6.597. [PMID: 8794970]
  • E Tanaka, N Sakamoto, M Inubushi, S Misawa. Simultaneous determination of plasma phenytoin and its primary hydroxylated metabolites in carbon tetrachloride-intoxicated rats by high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications. 1995 Nov; 673(1):147-51. doi: 10.1016/0378-4347(95)00250-m. [PMID: 8925069]
  • N B O'Mara, P R Jones, D L Anglin, S Cox, M C Nahata. Pharmacokinetics of phenytoin in children with acute neurotrauma. Critical care medicine. 1995 Aug; 23(8):1418-24. doi: 10.1097/00003246-199508000-00017. [PMID: 7634814]
  • I Ieiri, W Goto, K Hirata, A Toshitani, S Imayama, Y Ohyama, H Yamada, K Ohtsubo, S Higuchi. Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study. European journal of clinical pharmacology. 1995; 49(1-2):51-6. doi: 10.1007/bf00192358. [PMID: 8751021]
  • M D Green, E M Oturu, T R Tephly. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug metabolism and disposition: the biological fate of chemicals. 1994 Sep; 22(5):799-805. doi: NULL. [PMID: 7835232]
  • C Desiderio, S Fanali, A Küpfer, W Thormann. Analysis of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in human urine by cyclodextrin micellar electrokinetic capillary chromatography: simple determination of a hydroxylation polymorphism in man. Electrophoresis. 1994 Jan; 15(1):87-93. doi: 10.1002/elps.1150150113. [PMID: 8143685]
  • M T Maya, A R Farinha, A M Lucas, J A Morais. Sensitive method for the determination of phenytoin in plasma, and phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in urine by high-performance liquid chromatography. Journal of pharmaceutical and biomedical analysis. 1992 Oct; 10(10-12):1001-6. doi: 10.1016/0731-7085(91)80111-l. [PMID: 1298355]
  • J Zeng, D Liu, Y Zou. [High performance liquid chromatographic determination of hydroxyphenytoin in human urine]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao. 1992 Sep; 23(3):321-4. doi: NULL. [PMID: 1298726]
  • M J Eadie, G E McKinnon, R G Dickinson, W D Hooper, C M Lander. Phenytoin metabolism during pregnancy. European journal of clinical pharmacology. 1992; 43(4):389-92. doi: 10.1007/bf02220614. [PMID: 1451718]
  • J D Huang, C Y Hsieh. Stereoselective inhibition of diphenylhydantoin metabolism by p-hydroxyphenyl-phenylhydantoin enantiomers in rats. Chirality. 1991; 3(6):454-9. doi: 10.1002/chir.530030608. [PMID: 1812955]
  • M A Moustafa, A A el-Emam, H I Subbagh, M K el-Din. Comparative study on the para-metabolic oxidation of phenytoin and decadeuteriophenytoin. Arzneimittel-Forschung. 1990 Oct; 40(10):1076-8. doi: NULL. [PMID: 2291743]
  • T B Vree, R P Steegers-Theunissen, A M Baars, Y A Hekster. Direct high-performance liquid chromatographic analysis of p-hydroxyphenyl-phenylhydantoin glucuronide, the final metabolite of phenytoin, in human serum and urine. Journal of chromatography. 1990 Apr; 526(2):581-9. doi: 10.1016/s0378-4347(00)82544-x. [PMID: 2362000]
  • T Inaba. Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation. Pharmacology & therapeutics. 1990; 46(3):341-7. doi: 10.1016/0163-7258(90)90022-t. [PMID: 2188267]
  • T Ogiso, Y Ito, M Iwaki, K Tsunekawa. Drug interaction between phenytoin and allopurinol. Journal of pharmacobio-dynamics. 1990 Jan; 13(1):36-43. doi: 10.1248/bpb1978.13.36. [PMID: 2341968]
  • B A Boucher, J H Rodman, G S Jaresko, S N Rasmussen, C B Watridge, T C Fabian. Phenytoin pharmacokinetics in critically ill trauma patients. Clinical pharmacology and therapeutics. 1988 Dec; 44(6):675-83. doi: 10.1038/clpt.1988.211. [PMID: 3197366]
  • J H Maguire. Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism. Epilepsia. 1988 Nov; 29(6):753-9. doi: 10.1111/j.1528-1157.1988.tb04231.x. [PMID: 3191891]
  • K S Siff, A E Finkler. False-positive barbiturate test in urine owing to phenytoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin. Clinical chemistry. 1988 Jun; 34(6):1359-60. doi: 10.1093/clinchem/34.6.1359a. [PMID: 3378341]
  • M A Moustafa, F Belal, A A el-Emam. Spectroscopic determination of the major metabolite of phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin in human urine. Journal de pharmacie de Belgique. 1987 Jan; 42(1):53-8. doi: NULL. [PMID: 3585688]
  • J T Lum, P G Wells. Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen. Teratology. 1986 Feb; 33(1):53-72. doi: 10.1002/tera.1420330109. [PMID: 3738810]
  • J H Maguire, J S McClanahan. Evidence for stereoselective production of phenytoin (5,5-diphenylhydantoin) arene oxides in man. Advances in experimental medicine and biology. 1986; 197(?):897-902. doi: 10.1007/978-1-4684-5134-4_85. [PMID: 3766299]
  • R Gugler, J C Jensen. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985 Dec; 89(6):1235-41. doi: 10.1016/0016-5085(85)90638-9. [PMID: 3932118]
  • K Shimada, H Wakabayashi, A Sato. Gas chromatographic determination of m- and p-hydroxyphenytoin in the urine of epileptic patients. Journal of chromatography. 1985 May; 339(2):331-7. doi: 10.1016/s0378-4347(00)84660-5. [PMID: 4008572]
  • B F Bourgeois, N Wad. Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio. Therapeutic drug monitoring. 1985; 7(4):405-10. doi: 10.1097/00007691-198512000-00007. [PMID: 4082240]
  • R G Dickinson, W D Hooper, M Patterson, M J Eadie, B Maguire. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Therapeutic drug monitoring. 1985; 7(3):283-9. doi: 10.1097/00007691-198507030-00008. [PMID: 4049465]
  • T M Hassell, J H Maguire, C G Cooper, P T Johnson. Phenytoin metabolism in the cat after long-term oral administration. Epilepsia. 1984 Oct; 25(5):556-63. doi: 10.1111/j.1528-1157.1984.tb03461.x. [PMID: 6479107]
  • D B Haughey, G R Matzke, C E Halstenson, W F Keane. Analytical specificity of commercially available methods for serum phenytoin determination. Journal of analytical toxicology. 1984 May; 8(3):106-11. doi: 10.1093/jat/8.3.106. [PMID: 6376948]
  • R J Sawchuk, G R Matzke. Contribution of 5-(4-hydroxyphenyl)-5-phenylhydantoin to the discrepancy between phenytoin analyses by EMIT and high-pressure liquid chromatography. Therapeutic drug monitoring. 1984; 6(1):97-103. doi: 10.1097/00007691-198403000-00016. [PMID: 6369645]
  • P N Patsalos, P T Lascelles. Metabolic interactions of phenytoin in the rat: effect of coadministration with the anticonvulsant drugs sodium valproate, sulthiame, ethosuximide or phenobarbital. General pharmacology. 1984; 15(1):7-12. doi: 10.1016/0306-3623(84)90072-7. [PMID: 6141984]
  • B Rambeck, T May. Urinary hydroxyphenytoin/creatinine ratios as an index of compliance in adult epileptic patients on phenytoin therapy. Therapeutic drug monitoring. 1984; 6(2):164-72. doi: 10.1097/00007691-198406000-00006. [PMID: 6740735]
  • F S Apple, F C Walker, D N Dietzler. Serum creatinine concentration and the discrepancy between enzyme multiplied immunoassay technique and gas-liquid chromatographic phenytoin levels. Annals of clinical and laboratory science. 1983 Sep; 13(5):385-92. doi: NULL. [PMID: 6357047]
  • Y Izumo, A Sato, K Shimada, T Sakaguchi, I Okabayashi, N Murakami. [Examination of phenytoin metabolites in rat urine]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 1983 Sep; 103(9):956-61. doi: 10.1248/yakushi1947.103.9_956. [PMID: 6371215]
  • U Jürgens. Routine determination of hydroxyphenytoin in urine by high-performance liquid chromatography using an automatic column-switching technique. Journal of chromatography. 1983 Jul; 275(2):335-43. doi: 10.1016/s0378-4347(00)84379-0. [PMID: 6619238]
  • A Sato, K Shimada, Y Izumo, T Sakaguchi. High-performance liquid chromatographic determination of phenytoin and hydroxyphenytoin in human urine. Journal of chromatography. 1983 Jun; 275(1):97-105. doi: 10.1016/s0378-4347(00)84348-0. [PMID: 6874875]
  • F A de Wolff, P Vermeij, M D Ferrari, O J Buruma, D D Breimer. Impairment of phenytoin parahydroxylation as a cause of severe intoxication. Therapeutic drug monitoring. 1983 Jun; 5(2):213-5. doi: 10.1097/00007691-198306000-00011. [PMID: 6879646]
  • M Claesen, M A Moustafa, J Adline, D Vandervorst, J H Poupaert. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and in man. Drug metabolism and disposition: the biological fate of chemicals. 1982 Nov; 10(6):667-71. doi: . [PMID: 6130920]
  • W E Dodson, L C Loney. Hemodialysis reduces the unbound phenytoin in plasma. The Journal of pediatrics. 1982 Sep; 101(3):465-8. doi: 10.1016/s0022-3476(82)80090-5. [PMID: 7108673]
  • R C Chou, G Levy. Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats. The Journal of pharmacology and experimental therapeutics. 1981 Oct; 219(1):42-8. doi: NULL. [PMID: 7288614]
  • A Van Langenhove, C E Costello, J E Biller, K Biemann, T R Browne. A gas chromatographic/mass spectrometric method for the simultaneous quantitation of 5,5-diphenylhydantoin (phenytoin), its para-hydroxylated metabolite and their stable isotope labelled analogs. Clinica chimica acta; international journal of clinical chemistry. 1981 Sep; 115(3):263-75. doi: 10.1016/0009-8981(81)90240-0. [PMID: 7028323]
  • T D O'Leary, L N Sansom. Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat. The Journal of pharmacology and experimental therapeutics. 1981 Mar; 216(3):613-6. doi: NULL. [PMID: 6782238]
  • F Sarhan, J M Engasser, A M Batt, J Magdalou, G Siest. Effect of diphenylhydantoin and its main hydroxylated metabolite on the pharmacokinetics and the urinary and biliary excretion of phenobarbital and its p-hydroxy metabolite. European journal of drug metabolism and pharmacokinetics. 1981; 6(2):99-108. doi: 10.1007/bf03189475. [PMID: 7306277]
  • A Sato, T Sakaguchi, K Shimada. [Quantitative measurement of phenytoin and hydroxyphenytoin in human serum by column extraction-high-performance liquid chromatography (author's transl)]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 1980 Dec; 100(12):1215-9. doi: 10.1248/yakushi1947.100.12_1215. [PMID: 7252778]
  • N K Kochenour, M G Emery, R J Sawchuk. Phenytoin metabolism in pregnancy. Obstetrics and gynecology. 1980 Nov; 56(5):577-82. doi: NULL. [PMID: 7432728]
  • D Couri, C Suarez del Villar, P T Toy-Manning. Simultaneous quantitative assay of phenobarbital, phenytoin, and p-hydroxydiphenylhydantoin by HPLC and a comparison with EMIT. Journal of analytical toxicology. 1980 Sep; 4(5):227-31. doi: 10.1093/jat/4.5.227. [PMID: 7003258]
  • R J Sawchuk, L L Cartier. Liquid-chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in plasma and urine. Clinical chemistry. 1980 Jun; 26(7):835-9. doi: NULL. [PMID: 7379305]
  • K M Witkin, D L Bius, B L Teague, L S Wiese, L W Boyles, K H Dudley. Determination of 5-(p-hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in man. Therapeutic drug monitoring. 1979; 1(1):11-34. doi: 10.1097/00007691-197901000-00003. [PMID: 553326]
  • P M Kabra, L J Marton. High-pressure liquid-chromatographic determination of 5-(4-hydroxyphenyl)-5-phenylhydantoin in humanurine. Clinical chemistry. 1976 Oct; 22(10):1672-4. doi: NULL. [PMID: 975513]
  • C Hoppel, M Garle, M Elander. Mass fragmentographic determination of diphenylhydantoin and its main metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, in human plasma. Journal of chromatography. 1976 Jan; 116(1):53-61. doi: 10.1016/s0021-9673(00)83699-7. [PMID: 1245573]